Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome

Maturitas

Volumn 55, Issue SUPPL. 1, 2006, Pages

  Prilepskaya, V N ^a   Ledina, A V ^a   Tagiyeva, A V ^a   Revazova, F S ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

BNO 1095; Premenstrual syndrome; Vitex agnus castus

Indexed keywords

BNO 1095; VITEX AGNUS CASTUS EXTRACT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ERYTHEMA; FEMALE; FLATULENCE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; NERVOUSNESS; PAIN; PERIPHERAL EDEMA; PREMENSTRUAL SYNDROME; PROSPECTIVE STUDY; PRURITUS; SIDE EFFECT; SKIN ALLERGY; STUDENT T TEST;

VITEX AGNUS-CASTUS;

EID: 33751076295     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.06.017     Document Type: Article

References (24)

1. Sternfeld B., Swindle R., Chawla A., Long S., and Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 99 (2002) 1014-1024
2. Singh B.B., Berman B.M., Simpson R.L., and Annchild A. Incidence of premenstrual symptome and remedy usage: a national probability sample study. Altern Ther Health Med 4 (1998) 75-79
3. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines of management. J Psychiatry Neurosci 45 (2000) 459-468
4. Wittchen H.U., Becker E., Liebt R., et al. Prevalence, incidence and stability of premenstrual dysphoric disorder. Psychol Med 32 (2002) 119-132
5. American Psychiatric Association. Diagnostic and statistical manual of mental disoders, 4th ed. Washington, DC: Am. Psychiatric Ass. Press; 1994.
6. Ho K.Y., and Thorner M.O. Therapeutic applications of bromcriptine in endocrine and neurological diseases. Drugs 36 (1988) 67-82
7. ®. Summary of product characteristics (Fachinformation), Novartis Pharma GmbH, Germany, status: February 2004.
8. The Register of medicines of Russia (Encyclopaedia of medicines), issue 9, 2002;170-1.
9. KiIicdag E.B., Tarim E., Bagis T., et al. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Gynaecol Obstet 85 (2004) 292-293
10. Wuttke W., Gorkow C., and Jarry H. Dopaminergic compounds in Vitex agnus castus. In: Loew R.N., and Darmstadt D. (Eds). Phytopharmaka in Foschung und klinischer Anwendung (1995), Steinkopff Verlag 81-91
11. Christoffel V., Spengler B., Abel G., Jarry H., and Wuttke W. Diterpenes from BNO 1095 (Vittex agnus castus) inhibit prolactin secretion. Proceedings of the 6th annual symposium on complementary health care. Exeter, UK (1999)
12. Jarry H, Christoffel V, Spengler B, Popp MA, Wuttke W. Diterpens isolated from Vitex agnus castus BNO 1095 inhibit prolactin secretion via specific interaction with dopamine D2 receptors in the pituitary, Jahrestagung der Ges. Für Phytotherapie, Münster; 1999.
13. Merz P.G., Gorkow C., Schrödter A., et al. The effects of a special Agnus Castus-extract (BP1095E1) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes 104 6 (1996) 447-453
14. Jarry H., Leonhardt S., Gorkow C., and Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 102 6 (1994) 448-454
15. Wuttke W., Jarry H., Christoffel V., Spengler B., and Seidlova-Wuttke D. Chaste-tree (Vitex agnus castus)-pharmacology and clinical indications. Phytomedicine 10 4 (2003) 348-357
16. Brugisser R., Burkard W., Simmen U., and Schaffner W. Untersuchungen an opioid-rezeptoren mit Vitex agnus castus L. Phytotherapie 20 3 (1999) 154-158
17. Hoberg E. Phytochemical and analytical investigations of Vitex agnus castus L. (dissertation) (1999), Swiss Federal Institute of Technology Zürich, Zürich, Switzerland Available from: Diss: ETH 13285
18. Lauritzen Ch, Reuter H.D., Repges R., Böhnert K.J., and Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-blind study vs. pyridoxine. Phytomedicine 4 (1997) 183-189
19. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 322 (2001) 134-137
20. Halaska M., Beles P., Gorkow C., and Sieder C. Treatment of ciclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast 8 4 (1999) 175-181
21. Atmaca M., Kumru S., and Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol Clin Exp 18 (2003) 191-195
22. Steiner M., Haskett R.F., and Carroll B.J. Premenstrual tension syndrome: the development or research diagnostic criteria and rating scale. Acta Psychiat Scand 62 (1980) 177-190
23. European Union, Eudralex, Vol. 9. Pharmacovigilance-Medicinal Products for Human use and Veterinary Medicinal Products, specifically therein Chapter 1.5; June/July 2004
24. Agnucaston, Summary of product characteristics (Fachinformation), Bionorica AG, Germany, status of information; February 2004